{"id":180266,"date":"2026-02-10T05:59:38","date_gmt":"2026-02-10T10:59:38","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180266"},"modified":"2026-02-10T06:44:01","modified_gmt":"2026-02-10T11:44:01","slug":"earnings-summary-aarti-pharmalabs-limited-reports-sequential-margin-recovery-in-q3-fy26-as-cdmo-transit-impact-weighs-on-revenue","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-summary-aarti-pharmalabs-limited-reports-sequential-margin-recovery-in-q3-fy26-as-cdmo-transit-impact-weighs-on-revenue\/","title":{"rendered":"Aarti Pharmalabs Limited reports sequential margin recovery in Q3 FY26 as CDMO transit impact weighs on revenue"},"content":{"rendered":"\n

Aarti Pharmalabs Limited (NSE: AARTIPHARM, BSE: 543748)<\/strong> reported a sequential improvement in operating performance in the quarter ended Dec. 31, 2025, as margins recovered quarter on quarter despite a year-on-year decline in revenue, according to the company\u2019s Q3 FY26 results presentation.<\/p>\n\n\n\n

Key Q3 FY26 highlights:<\/strong><\/h2>\n\n\n\n
    \n
  • Operational revenue stood at \u20b94,253 million<\/strong>, up 1.9% quarter on quarter<\/strong> and down 9.7% year on year<\/strong>.<\/li>\n\n\n\n
  • EBITDA rose 39.0% quarter on quarter to \u20b91,030 million<\/strong>.<\/li>\n\n\n\n
  • EBITDA margin expanded to 24.22%<\/strong>, up 646 bps sequentially<\/strong>.<\/li>\n\n\n\n
  • Profit after tax increased 41.7% quarter on quarter to \u20b9438 million<\/strong>.<\/li>\n\n\n\n
  • CDMO\/CMO revenue was impacted by \u20b949 crore of goods in transit<\/strong> that could not be booked in Q3 FY26.<\/li>\n\n\n\n
  • Xanthine expansion project remained on track, with mechanical completion targeted by March 2026<\/strong>.<\/li>\n<\/ul>\n\n\n\n

    Q3 FY26 financial performance<\/h2>\n\n\n\n

    On a standalone basis, operational revenue declined year on year due to lower volumes in certain API segments and deferred revenue recognition in CDMO\/CMO. Operating expenses fell 6.1% quarter on quarter<\/strong>, supporting margin recovery.<\/p>\n\n\n\n

    EBITDA of \u20b91,030 million<\/strong> reflected improved operating leverage and cost control, while profit after tax of \u20b9438 million<\/strong> rose sharply sequentially. Year on year, PAT declined due to a higher base in Q3 FY25 and softer API margins. Depreciation and finance costs increased year on year, reflecting ongoing capacity additions and higher borrowings.<\/p>\n\n\n\n

    Segment trends<\/h2>\n\n\n\n

    Xanthine derivatives<\/strong> continued to be the largest contributor to quarterly revenue, accounting for 48.9%<\/strong> of sales in Q3 FY26, up from 44.1%<\/strong> in Q3 FY25. The company is executing a capacity expansion program to raise Xanthine capacity from 5,000 MTPA to 9,000 MTPA<\/strong>, with phased commissioning expected in the second half of FY26. Management targets increasing global market share from 15%\u201320% to 20%\u201325%<\/strong> post-expansion.<\/p>\n\n\n\n

    API & intermediates<\/strong> faced margin pressure despite early signs of demand recovery, while CDMO\/CMO<\/strong> revenues were temporarily impacted by revenue recognition timing. The company said \u20b949 crore of CDMO shipments were in transit<\/strong> at quarter-end and are expected to be recognized in subsequent periods.<\/p>\n\n\n\n

    Nine-month FY26 performance<\/h2>\n\n\n\n

    For the nine months ended Dec. 31, 2025, standalone operational revenue declined 1.9% year on year to \u20b912,179 million<\/strong>. EBITDA fell 4.0% to \u20b92,720 million<\/strong>, with the EBITDA margin at 22.33%<\/strong>. PAT declined 25.2% to \u20b91,260 million<\/strong>, reflecting weaker year-on-year performance in APIs and higher finance costs.<\/p>\n\n\n\n

    On a consolidated basis, 9M FY26 operational revenue stood at \u20b912,368 million<\/strong>, while PAT was \u20b91,254 million<\/strong>. The company noted that consolidated numbers are not directly comparable year on year due to a change in accounting for a joint venture effective April 2025.<\/p>\n\n\n\n

    Capacity expansion and capex<\/h2>\n\n\n\n

    The company is advancing two major capex programs. The Atali greenfield site in Gujarat<\/strong> (Phase 1 capacity ~450 KL) is expected to ramp up by Q4 FY26<\/strong>, although operational challenges impacted the pace of ramp-up in the quarter. The Tarapur brownfield expansion<\/strong> will lift Xanthine capacity to 9,000 MTPA<\/strong>, with commissioning targeted for Q4 FY26<\/strong>. Management said the Atali site is scalable to 8\u201310x<\/strong> of Phase 1 capacity over time.<\/p>\n\n\n\n

    Outlook<\/h2>\n\n\n\n

    Management expects sequential improvement in CDMO\/CMO revenue as in-transit shipments are recognized and ramp-up issues at Atali are resolved. Xanthine capacity additions are expected to support volume growth and market share gains, while API margins remain under pressure in the near term.<\/p>\n\n\n\n

    Summary<\/h2>\n\n\n\n

    Aarti Pharmalabs delivered a sequential recovery in margins and profit in Q3 FY26, despite lower year-on-year revenue due to deferred CDMO recognition and API margin pressure. Capacity expansions in Xanthine and CDMO\/intermediates remain key growth drivers for the second half of FY26 and beyond.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Aarti Pharmalabs Limited (NSE: AARTIPHARM, BSE: 543748) reported a sequential improvement in operating performance in the quarter ended Dec. 31, 2025, as margins recovered quarter on quarter despite a year-on-year decline in revenue, according to the company\u2019s Q3 FY26 results presentation. Key Q3 FY26 highlights: Q3 FY26 financial performance On a standalone basis, operational revenue […]<\/p>\n","protected":false},"author":2409,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392,5747],"tags":[16133,16135,16136,15997,16139,16142,15995,16138,16140,16137,15062,10089,16134,16141],"class_list":["post-180266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-aarti-pharmalabs","tag-atali-facility","tag-bse-543748","tag-capacity-expansion","tag-cdmo-business","tag-ebitda-margin-recovery","tag-investor-presentation","tag-nse-aartipharm","tag-pharmaceutical-apis","tag-profit-growth-qoq","tag-q3-fy26-results","tag-quarterly-earnings","tag-tarapur-expansion","tag-xanthine-derivatives"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170458,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-q1-fy26-earnings-results\/","url_meta":{"origin":180266,"position":0},"title":"Aarti Pharmalabs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Pharmalabs Ltd, incorporated in 2019, is a manufacturer of pharmaceuticals and nutraceuticals. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9386 crore, down 30.45% year-on-year (YoY) from \u20b9555 crore in Q1 FY25. Total Expenses: \u20b9323 crore, down 33.26% YoY from \u20b9484 crore. Consolidated Net\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIPAHRM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172328,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-q2-fy26-earnings-results\/","url_meta":{"origin":180266,"position":1},"title":"Aarti Pharmalabs Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 11, 2025","format":false,"excerpt":"Aarti Pharmalabs Ltd, incorporated in 2019 and engaged in manufacturing pharmaceuticals and nutraceuticals, reported its Q2FY26 financial results indicating challenges in profitability. Financial Highlights: Revenues declined 8.73% year-on-year to \u20b9418 crore from \u20b9458 crore. Total expenses decreased 2.81% to \u20b9380 crore from \u20b9391 crore. Consolidated net profit dropped 49.09% to\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177629,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-reports-q3-fy26-revenue-of-%e2%82%b92-9-billion-ebitda-declines-amid-approval-delays\/","url_meta":{"origin":180266,"position":2},"title":"OneSource Specialty Pharma Ltd reports Q3 FY26 revenue of \u20b92.9 billion, EBITDA declines amid approval delays","author":"Staff Correspondent","date":"January 24, 2026","format":false,"excerpt":"OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) reported consolidated revenue of \u20b92.9 billion for the quarter ended December 31, 2025, a decline of 26% year-on-year, according to its Q3 FY26 earnings release. EBITDA stood at \u20b9173 million, down 88% from the corresponding quarter last year, while adjusted profit\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179740,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-viyash-reports-higher-revenue-and-margins-in-first-merged-entity-quarter\/","url_meta":{"origin":180266,"position":3},"title":"Sequent Scientific (Viyash) reports higher revenue and margins in first merged-entity quarter","author":"Staff Correspondent","date":"February 5, 2026","format":false,"excerpt":"Sequent Scientific Limited (now Viyash Scientific Limited) (BSE: 512529 \/ NSE: SEQUENT) reported higher revenue and profitability in the quarter ended December 31, 2025, reflecting growth in its formulations, APIs and CDMO businesses in the first quarter reported on a combined post-merger basis. For Q3 FY26, consolidated revenue rose 10.9%\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166314,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-ltd-q2fy25-6-rise-in-profits\/","url_meta":{"origin":180266,"position":4},"title":"Aarti Pharmalabs Ltd Q2FY25; 6% rise in Profits","author":"Divyansh_Kasana","date":"January 10, 2025","format":false,"excerpt":"Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals Financial Results: Aarti Pharmalabs Ltd reported Revenues for Q2FY25 of \u20b9458.00 Crores up from \u20b9440.00 Crore year on year, a rise of 4.09%. Total Expenses for Q2FY25 of \u20b9391.00 Crores up from \u20b9374.00 Crores year on year,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/H-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/H-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/H-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/H-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/H-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/H-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":161945,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-ltd-q4fy24-51-rise-in-profits\/","url_meta":{"origin":180266,"position":5},"title":"Aarti Pharmalabs Ltd Q4FY24; 51% rise in Profits","author":"Divyansh_Kasana","date":"June 6, 2024","format":false,"excerpt":"Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals Financial Results: Aarti Pharmalabs Ltd reported Revenues for Q4FY24 of \u20b9506.00 Crores up from \u20b9485.00 Crore year on year, a rise of 4.33%. Total Expenses for Q4FY24 of \u20b9412.00 Crores down from \u20b9427.00 Crores year on year,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-61.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-61.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-61.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-61.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-61.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-61.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2409"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180266"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180266\/revisions"}],"predecessor-version":[{"id":180277,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180266\/revisions\/180277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}